Floatz logo

Fuzuloparib

Fatty Liver Disease

Universitas DiponegoroN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Fatty Liver Disease cohort.

Asset / SponsorPhaseRating
Dolutegravir
Fundacion SEIMC-GESIDA
Phase 4BB
Rilpivirine
Fundacion SEIMC-GESIDA
Phase 4BB
TENOFOVIR DISOPROXIL FUMARATE
Fundacion SEIMC-GESIDA
Phase 4BB
Tenofovir Alafenamide
Fundacion SEIMC-GESIDA
Phase 4BB
(±)-FTC
Fundacion SEIMC-GESIDA
Phase 4BB

View all 13 →

Same molecule, other indications

Fuzuloparib is also rated in:

Obese Patients With Prostate Cancer DiseaseDormant
B
Indicative ·
60 / 100
View asset →
Chronic Postsurgical PainDormant
B
Indicative ·
60 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →